Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Neurog3 gene dosage regulates allocation of endocrine and exocrine cell fates in the developing mouse pancreas.

Developmental biology | 2010

The basic helix-loop-helix transcription factor Neurog3 (Neurogenin3 or Ngn3) actively drives endodermal progenitor cells towards endocrine islet cell differentiation during embryogenesis. Here, we manipulate Neurog3 expression levels in endocrine progenitor cells without altering its expression pattern using heterozygosity and a hypomorph. Lowered Neurog3 gene dosage in the developing pancreatic epithelium reduces the overall production of endocrine islet cells without significantly affecting the proportions of various islet cell types that do form. A reduced Neurog3 production level in the endocrine-directed pancreatic progenitor population activates the expression of Neurog3 in an increased number of epithelial progenitors. Yet a significant number of these Neurog3+ cells detected in heterozygous and hypomorphic pancreata, possibly those that express low levels of Neurog3, move on to adopt pancreatic ductal or acinar fates. These data directly demonstrate that achieving high levels of Neurog3 expression is a critical step for endocrine commitment from multipotent pancreatic progenitors. These findings also suggest that a high level of Neurog3 expression could mediate lateral inhibition or other unknown feedback mechanisms to regulate the number of cells that initiate Neurog3 transcription and protein production. The control of Neurog3+ cell number and the Neurog3 threshold-dependent endocrine differentiation mechanism combine to select a specific proportion of pancreatic progenitor cells to adopt the islet cell fate.

Pubmed ID: 20025861 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: P30 CA68485
  • Agency: NIDDK NIH HHS, United States
    Id: P30 DK058404
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK065949
  • Agency: NIDDK NIH HHS, United States
    Id: DK065949
  • Agency: NCI NIH HHS, United States
    Id: P30 CA068485
  • Agency: NIDDK NIH HHS, United States
    Id: P30DK058404
  • Agency: NIDDK NIH HHS, United States
    Id: DK42502
  • Agency: NIDDK NIH HHS, United States
    Id: R01 DK065949-06A2
  • Agency: NIDDK NIH HHS, United States
    Id: U19 DK042502
  • Agency: NIDDK NIH HHS, United States
    Id: DK058404
  • Agency: NIDDK NIH HHS, United States
    Id: P01 DK042502

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Charles River Laboratories (tool)

RRID:SCR_003792

Commercial organism provider selling mice, rats and other model animals. American corporation specializing in a variety of pre-clinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted biomedical products and research and development outsourcing services for use in the pharmaceutical industry. (Wikipedia)

View all literature mentions